Company
Headquarters: Shenyang, China
Employees: 1,102
CN¥18.16 Billion
CNY as of Jan. 1, 2026
US$2.59 Billion
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥2.41 B |
| EBITDA | CN¥598.2 M |
| Gross Profit TTM | CN¥1.94 B |
| Profit Margin | 26.84% |
| Operating Margin | 44.65% |
| Quarterly Revenue Growth | 35.30% |
Shenyang Xingqi Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300573 wb_incandescent